Avaleht/Aktsiad/IXHL

IXHL

USD

Incannex Healthcare Inc. Common Stock

$0.339-0.005 (-1.480%)

Reaalajas hind

Healthcare

Drug Manufacturers - Specialty & Generic

Austraalia

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Turunäitajad

Avatud

$0.344

Kõrge

$0.349

Madal

$0.336

Maht

15.84M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

118.0M

Tööstusharu

Drug Manufacturers - Specialty & Generic

Riik

Australia

Kauplemisstatistika

Keskmine maht

66.44M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $0.08Praegune $0.339Kõrge $3.12

Seotud uudised

26. aug 2025 · 12:00

GlobeNewswire

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company") is pleased to report positive data from its Phase 2 clinical trial of PSX-001

Vaata rohkem

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

22. aug 2025 · 12:00

GlobeNewswire

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination

Vaata rohkem

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

8. aug 2025 · 12:00

GlobeNewswire

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

MELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for prevalent medical

Vaata rohkem